LightOx is developing a light-activated chemotherapy treatment using photosensitizing agents to target early-stage oral cancer lesions, which allows for localized therapy with reduced side effects compared to traditional surgical methods. The company is currently completing pre-clinical testing and plans to initiate Phase I/IIa clinical trials in 2025.
Funding
$1.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Early-stage oral cancer lesions are typically treated with surgery, which can result in significant side effects and functional impairment for patients. Current treatment options lack targeted approaches, leading to unnecessary damage to healthy tissue surrounding the cancerous area.
Solution
LightOx is developing a light-activated chemotherapy treatment that uses photosensitizing agents to selectively target and destroy early-stage oral cancer lesions. The treatment involves applying a gel containing the photosensitizing drug to the affected area, followed by activation with a specific wavelength of light. This localized approach aims to minimize damage to surrounding healthy tissue, reducing side effects compared to traditional surgical methods. The technology has potential applications beyond oncology, including bacterial, fungal, and plant species.
Target Audience
The primary target audience includes patients with early-stage oral cancer lesions and the clinicians (dentists and oncologists) who treat them.
Features
- LXD191: A novel class of light-activated chemotherapy for oral cancer treatment.
- Photosensitizing agents: Designed to selectively target and kill cancer cells upon light activation.
- Topical gel application: Allows for direct and localized drug delivery to the lesion.
- Light activation: Enables precise control over the treatment area, minimizing off-target effects.
- Potential for use in a dentist's chair: Offers a quick and simple treatment modality.